Opinion
Video
The Logistical Challenges in ccRCC Treatment
Panelists discuss how the logistical challenge of the new test requiring separate appointments (tracer injection followed by imaging 5 days later) is offset by scheduling flexibility because of the tracer’s 78-hour half-life and the technology essentially providing a “virtual biopsy” without invasive procedures.
Practical Considerations for Implementation
Main Discussion Topics:
- Logistical challenges requiring separate appointments for tracer administration and imaging
- Imaging window is 5 days (± 2 days) after tracer injection.
- Long half-life (78 hours) provides flexibility in scheduling
- Comparison with prostate-specific membrane antigen tracers, which require same-day imaging.
Key Points for Physicians:
- Requires 2 separate patient visits: one for tracer injection, another for imaging.
- A 5-day interval between injection and imaging (with 2-day flexibility)
- A 96-hour shelf life provides scheduling flexibility.
- Noninvasive approach compared with biopsy with comparable diagnostic performance
Notable Insights:
Despite logistical considerations requiring 2 visits, the experts view this as a “virtual biopsy,” with performance characteristics similar to actual tissue sampling but without invasiveness.
Clinical Significance:
The logistical requirements are outweighed by the potential clinical value and noninvasive nature of the test compared with biopsy alternatives.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
